KLIFO 2025 Annual Report
A Year of Expanding Capacity and Strategic Transformation
Glostrup, Denmark – KLIFO, a leading Drug Development Consultancy and full-service Clinical Trial Supply provider, has released its Annual Report for the financial year ending 31 December 2025. The year was defined by major investment to expand the CTS capacity, as well as the completion of a strategic transformation, setting the company on a clear path for profitable growth.
Financial Highlights
KLIFO reported a underlying EBITDA* of DKK 5.8 million for 2025. The financial result was impacted by non-recurring costs related to i) the investment in the new Clinical Trial Supply facility in the Copenhagen area, and ii) the closure of discontinued clinical operations in Germany and the Netherlands.
Excluding these non-recurring items, the underlying performance remained stable, supported by continued demand and growth within KLIFO’s core services.
*) EBITDA equals Profit before net financials adjusted for depreciation and amortization.
Notable Milestones from 2025
KLIFO implemented a strategic realignment during 2025 to reinforce its core strengths within Clinical Trial Supply and Drug Development Consultancy. Notable milestones following this include:
- New Clinical Trial Supply Facility: A landmark milestone of 2025 was the successful opening of KLIFO’s new Clinical Trial Supply facility in the Copenhagen area. The state-of-the-art site significantly expands capacity, making it one of the largest facilities of its kind in Northern Europe, creating a strong platform for growth.
- KLIFO completed the discontinuation of its clinical research operations in Germany and the Netherlands following the completion of key customer projects and a prolonged slowdown in the biotech market in Central Europe.
- Premium Advisory Model: KLIFO continued to accelerate its transition towards a premium, expertise-led advisory model, leveraging its strong client relationships and deep capabilities across the full spectrum of drug development.
- Change in Management: 2025 saw important changes to KLIFO’s leadership. René Pedersen was appointed as Chief Executive Officer. René has been CFO of KLIFO for a number of years and is redoubling strategic clarity, direction setting and execution at KLIFO. In addition, a new Executive Vice President for the Drug Development Consultancy area, Rasmus Rabøl, was appointed, reinforcing KLIFO’s commitment to growing and professionalizing its drug advisory offering.
Looking Ahead
With the transformation complete, KLIFO enters 2026 with a leaner, more focused structure and stronger capabilities than ever before. The investments made in 2025 lay a solid foundation for improved financial performance, and KLIFO continues to explore M&A opportunities and strategic partnerships to further accelerate growth.
“2025 marked the completion of a transition for KLIFO, combining targeted investment in our CTS platform and Advisory with the exit from non-core activities in Germany and the Netherlands. This positions our company for profitable growth going forward” said René Pedersen, CEO of KLIFO and adds “Our investment in a new, large-scale CTS facility demonstrates the confidence we have in our growth potential. With a growing pipeline in our CTS business and strong demand for our Drug Development Consultancy services, we look forward to the opportunities that lie ahead.”
